ssbet77 app download latest version
NoneTax reforms will eliminate traces of colonial rule in Nigeria’s economy — Tinubu( MENAFN - GlobeNewsWire - Nasdaq) KELLOGG, Idaho and VANCOUVER, British Columbia, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Bunker Hill mining Corp. (“ Bunker Hill ” or the“ Company ”) ( TSXV:BNKR | OTCQB:BHLL ) announces certain updates to its news release dated December 20, 2024 in connection with the Company's election to issue an aggregate of up to 8,446,194 shares of common stock of the Company (“ Common Shares ”) in full satisfaction of debenture interest payment obligations and outstanding financing cooperation fees, including: (i) an aggregate of up to 7,392,859 Common Shares (the“ Interest Shares ”) to certain holders of 7.5% convertible debentures (the“ Series 1 Convertible Debentures ”) and 10.5% convertible debentures (the“ Series 2 Convertible Debentures ” and, together with the Series 1 Convertible Debentures, the“ Convertible Debentures ”) in full satisfaction of the interest payable thereunder as of December 31, 2024 in the aggregate amount of USD$517,500.00 (the“ Interest Payment ”); and (ii) an aggregate of up to 1,053,335 Common Shares to a certain service provider of the Company (the“ Service Provider ”) in full satisfaction of the Q3 Cooperation Fee and Q4 Cooperation Fee (each as defined below). Convertible Debentures In accordance with the terms of the Convertible Debentures, the Company will issue the Interest Shares at a price of USD$0.07 per Interest Share based on 90% of the 10-day volume weighted average trading price of the Common Shares on the TSX Venture Exchange (the“ TSX-V ”) on the trading days beginning on December 9, 2024 and ending on December 20, 2024 (the“ Pricing Period ”). Further to its news release dated December 20, 2024, the Company will issue an aggregate of up to 7,119,049 Interest Shares to certain managed accounts of Sprott Private Resource Streaming and Royalty Corp. (“ Sprott ”) in connection with the Interest Payment, instead of 7,392,859 Interest Shares as previously disclosed. Accordingly, the issuance of such Interest Shares to Sprott will constitute a“related party transaction” within the meaning of Multilateral Instrument 61-101 – Protection of Minority Shareholder Approval (“ MI 61-101 ”). The Company will rely on exemptions from the formal valuation and minority shareholder approval requirements under MI 61-101 as neither the fair market value of the Interest Shares to be issued to Sprott, nor the consideration received for such Interest Shares, will exceed 25% of the Company's market capitalization. Financing Cooperation Fee The Settlement Shares are being issued pursuant to the terms of an agreement re financing cooperation dated September 27, 2022 (the“ Cooperation Agreement ”) entered into by and among the Company, its wholly owned subsidiary Silver Valley Metals Corp. (“ Silver Valley ”), the Service Provider and the Service Provider's affiliates, in consideration for the Service Provider and its affiliates providing certain collateral security in order for the Company and Silver Valley to obtain certain surety bonds with respect to the Bunker Hill Mine (the“ Collateral Security ”). The Company has elected to issue up to 509,480 Common Shares (each, a“ Q3 Share ”) at a deemed issue price of C$0.16 per Q3 Share to the Service Provider in full satisfaction of the aggregate US$60,000 financing cooperation fee owing to the Service Provider for providing the Collateral Security for the three (3) month period ending on September 30, 2024 (the“ Q3 Cooperation Fee ”). T he Company also intends to issue up to 543,855 Common Shares (each, a“ Q2 Share ” and, together with the Q3 Shares, the“ Settlement Shares ”) at a deemed issue price of C$0.15 per Q2 Share in full satisfaction of the US$60,000 financing cooperation fee owing to the Service Provider for providing the Collateral Security for the three (3) month period ending on June 30, 2024. In accordance with the terms of the Cooperation Agreement, the Company elected to issue the Settlement Shares in lieu of paying cash to preserve its cash for the potential restart and ongoing development of the Bunker Hill Mine. The issuance of the Common Shares described above remains subject to the receipt of all regulatory and stock exchange approvals. Once issued, the Interest Shares and the Settlement Shares will each be subject to a four (4) month and one (1) day hold period from the applicable date of issuance in accordance with applicable Canadian securities laws. The Interest Shares and the Settlement Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the“ U.S. Securities Act ”) or any U.S. state securities laws, and may not be offered or sold in the United States without registration under the U.S. Securities Act and all applicable state securities laws or in compliance with the requirements of an applicable exemption therefrom. ABOUT BUNKER HILL MINING CORP. Under Idaho-based leadership, Bunker Hill intends to sustainably restart and develop the Bunker Hill Mine as the first step in consolidating and then optimizing a number of mining assets into a high-value portfolio of operations, centered initially in North America. Information about the Company is available on its website, , or within the SEDAR+ and EDGAR databases. On behalf of Bunker Hill Sam Ash President, Chief Executive Officer and Director For additional information, please contact: Brenda Dayton Vice President, Investor Relations T: 604.417.7952 E: ... Cautionary Statements Neither the TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accepts responsibility for the adequacy or accuracy of this news release. Certain statements in this news release are forward-looking and involve a number of risks and uncertainties. Such forward-looking statements are within the meaning of that term in Section 27A of the U.S. Securities Act and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, as well as within the meaning of the phrase 'forward-looking information' in the Canadian Securities Administrators' National Instrument 51-102 – Continuous Disclosure Obligations (collectively,“ forward-looking statements ”). Forward-looking statements are not comprised of historical facts. Forward-looking statements include estimates and statements that describe the Company's future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as“believes”,“anticipates”,“expects”,“estimates”,“may”,“could”,“would”,“will”,“plan” or variations of such words and phrases. Forward-looking statements in this news release include, but are not limited to, statements regarding: the Company's objectives, goals or future plans, including the restart and development of the Bunker Hill Mine; the achievement of future short-term, medium-term and long-term operational strategies; the terms and completion of the share transactions described herein, including the number and deemed pricing of the Interest Shares and the Settlement Shares, respectively, issuable in connection therewith, and the Company receiving all regulatory and stock exchange approvals for the share transactions described herein. Forward-looking statements reflect material expectations and assumptions, including, without limitation, expectations and assumptions relating to: Bunker Hill's ability to complete the share transactions on the terms described herein or at all; Bunker Hill's ability to receive sufficient project financing for the restart and ongoing development of the Bunker Hill Mine on acceptable terms or at all; the future price of metals; and the stability of the financial and capital markets. Factors that could cause actual results to differ materially from such forward-looking statements include, but are not limited to, those risks and uncertainties identified in public filings made by Bunker Hill with the U.S. Securities and Exchange Commission (the“ SEC ”) and with applicable Canadian securities regulatory authorities, and the following: the Company's inability to raise additional capital for project activities, including through equity financings, concentrate offtake financings or otherwise; capital market conditions; restrictions on labor and its effects on international travel and supply chains; failure to identify mineral resources; failure to convert estimated mineral resources to reserves; the preliminary nature of metallurgical test results; the Company's ability to restart and develop the Bunker Hill Mine and the risks of not basing a production decision on a feasibility study of mineral reserves demonstrating economic and technical viability, resulting in increased uncertainty due to multiple technical and economic risks of failure which are associated with this production decision including, among others, areas that are analyzed in more detail in a feasibility study, such as applying economic analysis to resources and reserves, more detailed metallurgy and a number of specialized studies in areas such as mining and recovery methods, market analysis, and environmental and community impacts and, as a result, there may be an increased uncertainty of achieving any particular level of recovery of minerals or the cost of such recovery, including increased risks associated with developing a commercially mineable deposit, with no guarantee that production will begin as anticipated or at all or that anticipated production costs will be achieved; failure to commence production would have a material adverse impact on the Company's ability to generate revenue and cash flow to fund operations; failure to achieve the anticipated production costs would have a material adverse impact on the Company's cash flow and future profitability; delays in obtaining or failures to obtain required governmental, environmental or other project approvals; political risks; changes in equity markets; uncertainties relating to the availability and costs of financing needed in the future; the inability of the Company to budget and manage its liquidity in light of the failure to obtain additional financing, including the ability of the Company to complete the payments pursuant to the terms of the agreement to acquire the Bunker Hill Mine complex; inflation; changes in exchange rates; fluctuations in commodity prices; delays in the development of projects; and capital, operating and reclamation costs varying significantly from estimates and the other risks involved in the mineral exploration and development industry. Although the Company believes that the assumptions and factors used in preparing the forward-looking statements in this news release are reasonable, undue reliance should not be placed on such statements or information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all, including as to whether or when the Company will achieve its project finance initiatives, or as to the actual size or terms of those financing initiatives. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. Readers are cautioned that the foregoing risks and uncertainties are not exhaustive. Additional information on these and other risk factors that could affect the Company's operations or financial results are included in the Company's annual report and may be accessed through the SEDAR+ website ( ) or through EDGAR on the SEC website ( ). MENAFN23122024004107003653ID1109025602 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.
NASSAU, Bahamas (AP) — Javon Small scored five of his 31 points in overtime and Tucker DeVries added key free throws late in regulation and finished with 16 points as West Virginia beat No. 3 Gonzaga 86-78 in the Battle 4 Atlantis on Wednesday. Small's layup with under 2 minutes left in OT gave West Virginia a 79-75 lead. After a Gonzaga miss, Sencire Harris hit two free throws to make it a six-point lead. With 27.1 seconds left, Harris made a steal and scored on a dunk for an eight-point lead, putting the game out of reach. Amani Hansberry scored a career-high 19 points and Toby Okani added 10 for West Virginia (3-2). Braden Huff scored 19 points and Khalif Battle 16 for Gonzaga (5-1). Gonzaga showed its depth, outscoring the West Virginia bench 30-2. West Virginia’s only loss was by 24 points at Pitt, but the rebuild under Darian DeVries is showing promise. Gonzaga turned it over at midcourt late in regulation when Tucker DeVries poked it away from Nolan Hickman and raced the other way before getting fouled. DeVries made two free throws with 5.9 seconds left to tie it at 71-all. Battle inbounded the ball and got it back, but lost control on a drive as time expired. The shorter Mountaineers outrebounded Gonzaga 42-36 and shot 50% in the second half, battling the Zags to a draw in the paint. Nembhard had 12 assists and just one turnover in 43 minutes, but was 1 of 10 from the field. West Virginia will play Louisville on Thursday in the winner's bracket. Gonzaga faces No. 14 Indiana on the consolation side. ___ Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP college basketball: https://apnews.com/hub/ap-top-25-college-basketball-poll and https://apnews.com/hub/college-basketballThe Ministry of Foreign Affairs has debunked claims of an ambassadorial nominees’ list circulating on social media, calling it fake and urging the public to disregard it. In a statement issued on Sunday, the ministry, through its acting spokesperson, Kimiebi Ebienfa, clarified that the appointment of ambassadors is the exclusive responsibility of the President. The statement emphasised that no such appointments have been made. “The Ministry of Foreign Affairs wishes to inform the general public to kindly disregard the fake list of Ambassadorial nominees, which is currently in circulation on some social media platforms. “The Ministry wishes to state unequivocally that the appointment of Ambassadors is the prerogative of Mr. President, and no such appointments have been made in that regard. The purported list should, therefore, be discountenanced,” the statement said. The ministry’s clarification follows growing concerns and confusion over the authenticity of the list of ambassadors.Ruud van Nistelrooy is reportedly set to be appointed as Leicester City's new manager, various British media outlets said on Wednesday. Van Nistelrooy recently left Manchester United after a short spell as interim manager and serving as assistant to Erik ten Hag. Leicester sacked Steve Cooper on Sunday after just 12 Premier League games in charge, with the Foxes 16th in the table and only one point above the relegation zone. Two of Van Nistelrooy's three wins in four games as United's caretaker boss in the past month came against Leicester in the League Cup and Premier League. The 48-year-old Dutchman has previous managerial experience from one year in charge of PSV Eindhoven from 2022 to 2023. Sky Sports reported that he could even be appointed in time to lead Leicester in their next game away at Brentford on Saturday. A prolific goalscorer, Van Nistelrooy enjoyed a glorious playing career, most notably at PSV, Man United and Real Madrid. (AFP)
Moody’s upgrades Sri Lanka’s rating to Caa1; outlook stable
AI is a Major Disruptor to Your Salesforce: How the Evolution of AI is Transforming Sales Teams
Neuroblastoma Drugs Market 2024-2031 Global Industry Analysis, Size, Share, Growth, Trends, and Forecast | Leading Players - United Therapeutics Corporation, APEIRON Biologics AG, Teva Pharmaceutical Industries Ltd 11-21-2024 08:58 PM CET | Health & Medicine Press release from: DataM Intelligence 4 Market Research LLP DataM Intelligence The latest report on Neuroblastoma Drugs Market offers valuable insights into emerging trends and pivotal developments within the market. It highlights significant growth opportunities that market participants can leverage, alongside strategic recommendations for capitalizing on these trends. This report serves as an indispensable tool for stakeholders seeking to deepen their understanding of the market landscape and identify actionable pathways for growth. By utilizing this in-depth analysis, stakeholders will gain the insights necessary to effectively adapt to shifting market conditions and strengthen their competitive position. Download a Free sample PDF (Use Corporate email ID to Get Higher Priority) at: - https://datamintelligence.com/download-sample/neuroblastoma-drugs-market The Global Neuroblastoma Drugs Market is expected to grow at a high CAGR during the forecast period (2024-2031). Market Dynamics The rising demand for anti-GD2 antibodies is expected to significantly drive the growth of the global neuroblastoma drugs market during the forecast period. Anti-GD2 monoclonal antibodies have emerged as a key therapeutic innovation in treating neuroblastoma, a challenging pediatric cancer. GD2, a cell surface antigen, is highly expressed on neuroblastoma cells. Targeting these antigens with anti-GD2 antibodies enables precise action against cancer cells while sparing healthy tissues, reducing the risk of systemic cytotoxic effects. This specificity has improved the treatment outcomes and overall quality of life for patients. For instance, Dinutuximab, the first FDA-approved anti-GD2 monoclonal antibody, has shown efficacy in treating high-risk neuroblastoma, becoming a cornerstone therapy in this segment. Its ability to trigger immune responses, such as antibody-dependent cell-mediated cytotoxicity (ADCC), has been crucial in combating neuroblastoma. The growing recognition of anti-GD2 therapies' effectiveness, coupled with their favorable safety profiles, has led to increasing prescriptions by healthcare professionals. Additionally, ongoing research and development of next-generation GD2-targeted therapies and combination regimens are anticipated to further expand the market. As awareness of neuroblastoma treatments grows and advancements in antibody-based cancer therapies continue, the demand for anti-GD2 antibodies will drive significant growth in the neuroblastoma drugs market. Key Developments: January 27, 2021, Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Waldenstrom's Macroglobulinemia. On-going Phase 1 study on CLR 131 in children, adolescents, and young adults with relapsed or refractory malignant solid tumors and recurrent or refractory malignant brain tumors, neuroblastoma for which there are no standard treatment options with curative potential. List of the Key Players in the Neuroblastoma Drugs Market: Cellectar Biosciences, INC, United Therapeutics Corporation, APEIRON Biologics AG, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services, Inc, MacroGenics, Bristol-Myers Squibb Company, Eli Lilly and Company, Marsala Biotech Inc, Pfizer Inc. Research Process: Both primary and secondary data sources have been used in the global Neuroblastoma Drugs Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges. Segment Covered in the Neuroblastoma Drugs Market: By Drug Type (Dinutuximab, Cisplatin, Doxorubicin, Vincristine, Etoposide, Others) By Distribution Channel (Hospital Pharmacies, Clinics, Cancer research institutes, Others) Regional Outlook: The global Neuroblastoma Drugs Market report focuses on six major regions: North America, South America, Europe, Asia Pacific, the Middle East, and Africa. Get Customization in the report as per your requirements+Exclusive Bundle & Multi-User Discounts: https://datamintelligence.com/customize/neuroblastoma-drugs-market Regional Analysis: The global Neuroblastoma Drugs Market report focuses on six major regions: North America, South America, Europe, Asia Pacific, the Middle East, and Africa. The report offers detailed insight into new product launches, new technology evolutions, innovative services, and ongoing R&D. The report discusses a qualitative and quantitative market analysis, including PEST analysis, SWOT analysis, and Porter's five force analysis. The Neuroblastoma Drugs Market report also provides fundamental details such as raw material sources, distribution networks, methodologies, production capacities, industry supply chain, and product specifications. **The full version of the report includes an in-depth analysis of emerging players and startups, which will provide valuable insights into the evolving market landscape and key strategies being adopted** Points Covered: ⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Neuroblastoma Drugs market segments, study objectives, and years considered. ⏩ Market Landscape: The competition in the Global Neuroblastoma Drugs Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies. ⏩ Companies Profiles: The global Neuroblastoma Drugs market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production. ⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study. ⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Neuroblastoma Drugs Market. ⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type. ⏩ Research Findings: This section of the report showcases the findings and analysis of the report. ⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided. Unlock Year-End Savings! Get Up to 30% Off: https://www.datamintelligence.com/buy-now-page?report=neuroblastoma-drugs-market Frequently Asked Questions ● What is the expected growth rate of the global Neuroblastoma Drugs market for the forecast period? ● What are the key driving factors that are responsible to shape the fate of the Neuroblastoma Drugs market during the forecast period? ● What will be the overall size of the market during the analysis period? ● What are the prominent market trends which influence the development of the Neuroblastoma Drugs market across various regions? ● Who are the key market players and the market strategies that have helped them to secure the leading position in the global Neuroblastoma Drugs market? ● What are the challenges and threats that are likely to act as a barrier to the growth of the Neuroblastoma Drugs market? ● What are the major opportunities that the companies can get to attain success in the world? Contact Us - Company Name: DataM Intelligence Contact Person: Sai Kiran Email: Sai.k@datamintelligence.com Phone: +1 877 441 4866 Website: https://www.datamintelligence.com About Us - DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology. Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele. This release was published on openPR.
The Lakshman Kadirgamar Institute of International Relations and Strategic Studies (LKI), in collaboration with the International Committee of the Red Cross (ICRC) hosted a panel discussion titled, “Artificial Intelligence (AI), Autonomous Weapons Systems (AWS) and contemporary challenges” at the LKI Lighthouse Auditorium on 19 December 2024. It was attended by diplomats, representatives of international organisations, senior officials of relevant Ministries and agencies, military personnel, leading researchers and university students. Delivering the keynote address at the event, the Foreign Affairs Ministry Additional Secretary for East Asia, the Middle East, and Africa Yasoja Gunasekera underscored the urgent need for global action to regulate Artificial Intelligence and Autonomous Weapons Systems. She emphasised that while AI has become integral to numerous sectors, its growing presence on the battlefield raises profound concerns regarding its application in weapon systems. The Additional Secretary recalled that it was under the Chairmanship of Sri Lanka in 2015, that the high contracting parties to the convention on Certain Conventional Weapons (CCW) agreed to elevate the discussion of LAWS from an informal expert led discussion to a State-led dialogue, leading to the establishment of the first meeting of the Group of Governmental Experts (GGE) at the 2016 CCW Review Conference. She noted that in addition to actively engaging in the GGE, in October 2021 Sri Lanka together with a wide cross regional group of 70 states co-sponsored the first Joint Statement on LAWS at the UNGA and supported the adoption of “the Pact for the Future” by the UNGA in September 2024. Sri Lanka strongly supports the negotiation of a legally binding instrument to prohibit and regulate LAWS and supports the UN Secretary General and the President of the ICRC’s joint appeal to establish new rules on AWS by 2026. Earlier welcoming the gathering, LKI Executive Director Ambassador Ravinatha Aryasinha said the event was intended to salute the role played by the ICRC which commemorated the 75th anniversary of the operation of the Geneva Conventions, without which the world might have been a different place. He recalled the ICRC’s contributions to Sri Lanka since establishing a presence in 1989, particularly during the armed conflict – escorting food and civilian convoys to the North and the East, facilitating immunisation drives, passing messages between the parties in conflict and enabling the return of the wounded and the dead on both sides, and post conflict assistance in mine clearance, disaster response, and in the search for missing persons. Across time, the ICRC had also played an important role in training the security forces on IHL compliance and engaged in prison visitations and supported the improvement of prison conditions. He observed that the theme of the discussion chosen on disarmament, besides being one where the ICRC and Sri Lanka closely collaborated globally, is the focus of several ongoing research endeavours of the LKI in recent times, along with ICT and its contemporary challenges. Delivering the opening remarks, ICRC Sri Lanka Head of Delegation Severine Chappaz focused on the continued relevance of IHL. Stressing that the main responsibility to apply IHL in good faith lies with States to mitigate human suffering, she underlined the importance of making IHL a national and international political priority. She also emphasised on aspects of IHL that are particularly relevant to Sri Lanka, including the post-conflict application of IHL, which applies specifically to the issue of missing persons, their right to be searched for, the right of their families to know the fate and whereabouts of their missing loved ones and the obligation to prevent people from going missing. She also referred to the significance of national integration of IHL where the National IHL committee of Sri Lanka plays a key role, training the armed forces in IHL, and the dissemination of IHL through academic and religious circles. In her remarks, Sri Lanka’s international engagement in the promotion and development of IHL, notably in the field of disarmament regulations, was also recognised. ICRC Regional Legal Advisor Prof. Andrei Kozik highlighted the novel humanitarian and legal challenges posed by technological developments including AI and AWS. Delving into the subject, he drew attention to the unique characteristics of AWS that heighten risks for civilians and raise challenges for IHL compliance. In his presentation, Prof. Kozik also clarified the ICRC’s position on AWS, stating that the ICRC calls for new rules that prohibit the use of “unpredictable” and “anti-personnel” autonomous weapons systems. It was noted that in this context, “unpredictability” refers to the discriminatory nature of AWS weapons while “anti-personnel” refers to autonomous weapons designed or used to target humans directly. The ICRC’s report titled “International Humanitarian Law and the challenges of contemporary armed conflicts” was referenced as a source to obtain an overview of some of the challenges for IHL posed by contemporary armed conflicts. The report broadly underscores the humanitarian consequences that could result from the potential loss of human control over the use of force in armed conflict. Sri Lankan Coordinator for the Global Campaign “Stop Killer Robots” Yanithra Kumaraguru underscored the critical role of ethics in shaping both the legal frameworks and the development of autonomous weapons, especially in areas where current laws may not provide clear guidance. She highlighted several key ethical concerns, including the challenge of ensuring that autonomous weapons comply with international humanitarian law principles and also questioned whether machines could reliably make life-and-death decisions without human biases, stressing the risks of errors that could lead to violations of human dignity. She further discussed the “moral accountability gap”, an ethical concern that extends beyond legal frameworks and asked whether responsibility for actions taken by autonomous weapons lies with designers, operators, or no one at all emphasising the dehumanising consequences of delegating such critical decisions to machines. Stressing the fact that some advocates for autonomous weapons argue that these technologies could lead to greater precision and fewer civilian casualties, Kumaraguru countered that those technological limitations, the unpredictable nature of conflict and the human realities of conflict make such claims overly idealistic. Defence Ministry Director of Media and Spokesman, and Institute of National Security Studies (INSS) Head Colonel Nalin Herath while acknowledging the ethical challenges posed highlighted the transformative impact of AI on modern warfare emphasising its potential for operational efficiency, noted how such weapons are reshaping combat strategies and in distinguishing civilians from military targets. He raised concern about the growing access of non-state actors to advanced technologies, which heightens unpredictability in conflicts and cautioned against the dangers posed by AI in terms of misinformation and disinformation. Stressing the absence of a global consensus on regulating AI in warfare, he called for caution and cooperation to ensure ethical use of AI and to prevent its misuse. National Innovation Agency (NIA) Chief Innovation Officer and Pugwash Sri Lanka Past President Prof. Ajith De Alwis addressed the dual-use nature of science, technology, and innovation, particularly in the context of autonomous weapons systems and AI. He noted that since the wright brothers’ revolutionary invention of flight in 1903 which within a decade was quickly adapted for bombing, historically technology had been weaponised. He pointed to the futility of questioning whether blame can be apportioned to autonomous weapons used in wars, what is more crucial is that states create the conditions to prevent wars from taking place in the first place. He emphasised the need for better prioritising of the use of AWS, rather than banning per se, and advocated for leveraging AI and autonomous systems for humanity’s benefit rather than their weaponisation. Pointing to the climate issue where time was running out and the emission trajectories being put into wrong trajectories by all the conflicts going on, he asked that researchers must be persuaded to become more socially responsible, as the scientists who walked out of the “Manhattan Project” which pursued the creation of the atomic bomb. He also advocated strengthening a UN led global mechanism supporting whistle blowing and asked that we push ourselves to value humanity more - touching on the Pugwash principles. Ambassador Aryasinha who moderated the panel discussion, reflecting on the challenges faced as Sri Lanka’s Permanent Representative in Geneva in presiding over the CCW during Sri Lanka’ Presidency of the CCW in 2015/2016 which secured a consensus to commence the discussion of LAWS at the level of States parties nearly a decade ago, regretted that movement had been slow and that many relevant States needed for effective regulation of AWS, opposed or remained ambivalent in supporting such regulation. While the ethical and legal arguments were not in doubt, greater moral persuasion and compromise would be needed to also carry those who already possess or are on the verge of possessing AWS from using them, as war fronts expand and armies seek to minimise casualties. During an almost hour-long discussion that followed, the audience pointed to the absence of a universal definition, highlighted gaps in International Humanitarian Law (IHL), the politicisation of AWS, the advances and limitations in distinguishing combatants from non-combatants, opaque decision-making, the ethical and legal issues concerned and the slow pace of regulation. They also impressed on the need for a Sri Lanka national policy on AI and AWS, suggested that smaller nations like Sri Lanka press for reforms to protect weaker states. Members of the panel explored the tension between technological innovation and ethical responsibility, emphasising alignment with IHL principles like distinction and proportionality. They underscored transparency in AI’s “black box” decision-making, gaps in IHL related to espionage and information warfare, and the relevance of Article 36 of the Geneva Conventions in reviewing new weapons. The session concluded by stressing collaboration, culturally informed ethical considerations, and practical, legally binding measures to balance technological advances with human oversight.
NoneTax reforms will eliminate traces of colonial rule in Nigeria’s economy — Tinubu( MENAFN - GlobeNewsWire - Nasdaq) KELLOGG, Idaho and VANCOUVER, British Columbia, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Bunker Hill mining Corp. (“ Bunker Hill ” or the“ Company ”) ( TSXV:BNKR | OTCQB:BHLL ) announces certain updates to its news release dated December 20, 2024 in connection with the Company's election to issue an aggregate of up to 8,446,194 shares of common stock of the Company (“ Common Shares ”) in full satisfaction of debenture interest payment obligations and outstanding financing cooperation fees, including: (i) an aggregate of up to 7,392,859 Common Shares (the“ Interest Shares ”) to certain holders of 7.5% convertible debentures (the“ Series 1 Convertible Debentures ”) and 10.5% convertible debentures (the“ Series 2 Convertible Debentures ” and, together with the Series 1 Convertible Debentures, the“ Convertible Debentures ”) in full satisfaction of the interest payable thereunder as of December 31, 2024 in the aggregate amount of USD$517,500.00 (the“ Interest Payment ”); and (ii) an aggregate of up to 1,053,335 Common Shares to a certain service provider of the Company (the“ Service Provider ”) in full satisfaction of the Q3 Cooperation Fee and Q4 Cooperation Fee (each as defined below). Convertible Debentures In accordance with the terms of the Convertible Debentures, the Company will issue the Interest Shares at a price of USD$0.07 per Interest Share based on 90% of the 10-day volume weighted average trading price of the Common Shares on the TSX Venture Exchange (the“ TSX-V ”) on the trading days beginning on December 9, 2024 and ending on December 20, 2024 (the“ Pricing Period ”). Further to its news release dated December 20, 2024, the Company will issue an aggregate of up to 7,119,049 Interest Shares to certain managed accounts of Sprott Private Resource Streaming and Royalty Corp. (“ Sprott ”) in connection with the Interest Payment, instead of 7,392,859 Interest Shares as previously disclosed. Accordingly, the issuance of such Interest Shares to Sprott will constitute a“related party transaction” within the meaning of Multilateral Instrument 61-101 – Protection of Minority Shareholder Approval (“ MI 61-101 ”). The Company will rely on exemptions from the formal valuation and minority shareholder approval requirements under MI 61-101 as neither the fair market value of the Interest Shares to be issued to Sprott, nor the consideration received for such Interest Shares, will exceed 25% of the Company's market capitalization. Financing Cooperation Fee The Settlement Shares are being issued pursuant to the terms of an agreement re financing cooperation dated September 27, 2022 (the“ Cooperation Agreement ”) entered into by and among the Company, its wholly owned subsidiary Silver Valley Metals Corp. (“ Silver Valley ”), the Service Provider and the Service Provider's affiliates, in consideration for the Service Provider and its affiliates providing certain collateral security in order for the Company and Silver Valley to obtain certain surety bonds with respect to the Bunker Hill Mine (the“ Collateral Security ”). The Company has elected to issue up to 509,480 Common Shares (each, a“ Q3 Share ”) at a deemed issue price of C$0.16 per Q3 Share to the Service Provider in full satisfaction of the aggregate US$60,000 financing cooperation fee owing to the Service Provider for providing the Collateral Security for the three (3) month period ending on September 30, 2024 (the“ Q3 Cooperation Fee ”). T he Company also intends to issue up to 543,855 Common Shares (each, a“ Q2 Share ” and, together with the Q3 Shares, the“ Settlement Shares ”) at a deemed issue price of C$0.15 per Q2 Share in full satisfaction of the US$60,000 financing cooperation fee owing to the Service Provider for providing the Collateral Security for the three (3) month period ending on June 30, 2024. In accordance with the terms of the Cooperation Agreement, the Company elected to issue the Settlement Shares in lieu of paying cash to preserve its cash for the potential restart and ongoing development of the Bunker Hill Mine. The issuance of the Common Shares described above remains subject to the receipt of all regulatory and stock exchange approvals. Once issued, the Interest Shares and the Settlement Shares will each be subject to a four (4) month and one (1) day hold period from the applicable date of issuance in accordance with applicable Canadian securities laws. The Interest Shares and the Settlement Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the“ U.S. Securities Act ”) or any U.S. state securities laws, and may not be offered or sold in the United States without registration under the U.S. Securities Act and all applicable state securities laws or in compliance with the requirements of an applicable exemption therefrom. ABOUT BUNKER HILL MINING CORP. Under Idaho-based leadership, Bunker Hill intends to sustainably restart and develop the Bunker Hill Mine as the first step in consolidating and then optimizing a number of mining assets into a high-value portfolio of operations, centered initially in North America. Information about the Company is available on its website, , or within the SEDAR+ and EDGAR databases. On behalf of Bunker Hill Sam Ash President, Chief Executive Officer and Director For additional information, please contact: Brenda Dayton Vice President, Investor Relations T: 604.417.7952 E: ... Cautionary Statements Neither the TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accepts responsibility for the adequacy or accuracy of this news release. Certain statements in this news release are forward-looking and involve a number of risks and uncertainties. Such forward-looking statements are within the meaning of that term in Section 27A of the U.S. Securities Act and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, as well as within the meaning of the phrase 'forward-looking information' in the Canadian Securities Administrators' National Instrument 51-102 – Continuous Disclosure Obligations (collectively,“ forward-looking statements ”). Forward-looking statements are not comprised of historical facts. Forward-looking statements include estimates and statements that describe the Company's future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as“believes”,“anticipates”,“expects”,“estimates”,“may”,“could”,“would”,“will”,“plan” or variations of such words and phrases. Forward-looking statements in this news release include, but are not limited to, statements regarding: the Company's objectives, goals or future plans, including the restart and development of the Bunker Hill Mine; the achievement of future short-term, medium-term and long-term operational strategies; the terms and completion of the share transactions described herein, including the number and deemed pricing of the Interest Shares and the Settlement Shares, respectively, issuable in connection therewith, and the Company receiving all regulatory and stock exchange approvals for the share transactions described herein. Forward-looking statements reflect material expectations and assumptions, including, without limitation, expectations and assumptions relating to: Bunker Hill's ability to complete the share transactions on the terms described herein or at all; Bunker Hill's ability to receive sufficient project financing for the restart and ongoing development of the Bunker Hill Mine on acceptable terms or at all; the future price of metals; and the stability of the financial and capital markets. Factors that could cause actual results to differ materially from such forward-looking statements include, but are not limited to, those risks and uncertainties identified in public filings made by Bunker Hill with the U.S. Securities and Exchange Commission (the“ SEC ”) and with applicable Canadian securities regulatory authorities, and the following: the Company's inability to raise additional capital for project activities, including through equity financings, concentrate offtake financings or otherwise; capital market conditions; restrictions on labor and its effects on international travel and supply chains; failure to identify mineral resources; failure to convert estimated mineral resources to reserves; the preliminary nature of metallurgical test results; the Company's ability to restart and develop the Bunker Hill Mine and the risks of not basing a production decision on a feasibility study of mineral reserves demonstrating economic and technical viability, resulting in increased uncertainty due to multiple technical and economic risks of failure which are associated with this production decision including, among others, areas that are analyzed in more detail in a feasibility study, such as applying economic analysis to resources and reserves, more detailed metallurgy and a number of specialized studies in areas such as mining and recovery methods, market analysis, and environmental and community impacts and, as a result, there may be an increased uncertainty of achieving any particular level of recovery of minerals or the cost of such recovery, including increased risks associated with developing a commercially mineable deposit, with no guarantee that production will begin as anticipated or at all or that anticipated production costs will be achieved; failure to commence production would have a material adverse impact on the Company's ability to generate revenue and cash flow to fund operations; failure to achieve the anticipated production costs would have a material adverse impact on the Company's cash flow and future profitability; delays in obtaining or failures to obtain required governmental, environmental or other project approvals; political risks; changes in equity markets; uncertainties relating to the availability and costs of financing needed in the future; the inability of the Company to budget and manage its liquidity in light of the failure to obtain additional financing, including the ability of the Company to complete the payments pursuant to the terms of the agreement to acquire the Bunker Hill Mine complex; inflation; changes in exchange rates; fluctuations in commodity prices; delays in the development of projects; and capital, operating and reclamation costs varying significantly from estimates and the other risks involved in the mineral exploration and development industry. Although the Company believes that the assumptions and factors used in preparing the forward-looking statements in this news release are reasonable, undue reliance should not be placed on such statements or information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all, including as to whether or when the Company will achieve its project finance initiatives, or as to the actual size or terms of those financing initiatives. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. Readers are cautioned that the foregoing risks and uncertainties are not exhaustive. Additional information on these and other risk factors that could affect the Company's operations or financial results are included in the Company's annual report and may be accessed through the SEDAR+ website ( ) or through EDGAR on the SEC website ( ). MENAFN23122024004107003653ID1109025602 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.
NASSAU, Bahamas (AP) — Javon Small scored five of his 31 points in overtime and Tucker DeVries added key free throws late in regulation and finished with 16 points as West Virginia beat No. 3 Gonzaga 86-78 in the Battle 4 Atlantis on Wednesday. Small's layup with under 2 minutes left in OT gave West Virginia a 79-75 lead. After a Gonzaga miss, Sencire Harris hit two free throws to make it a six-point lead. With 27.1 seconds left, Harris made a steal and scored on a dunk for an eight-point lead, putting the game out of reach. Amani Hansberry scored a career-high 19 points and Toby Okani added 10 for West Virginia (3-2). Braden Huff scored 19 points and Khalif Battle 16 for Gonzaga (5-1). Gonzaga showed its depth, outscoring the West Virginia bench 30-2. West Virginia’s only loss was by 24 points at Pitt, but the rebuild under Darian DeVries is showing promise. Gonzaga turned it over at midcourt late in regulation when Tucker DeVries poked it away from Nolan Hickman and raced the other way before getting fouled. DeVries made two free throws with 5.9 seconds left to tie it at 71-all. Battle inbounded the ball and got it back, but lost control on a drive as time expired. The shorter Mountaineers outrebounded Gonzaga 42-36 and shot 50% in the second half, battling the Zags to a draw in the paint. Nembhard had 12 assists and just one turnover in 43 minutes, but was 1 of 10 from the field. West Virginia will play Louisville on Thursday in the winner's bracket. Gonzaga faces No. 14 Indiana on the consolation side. ___ Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP college basketball: https://apnews.com/hub/ap-top-25-college-basketball-poll and https://apnews.com/hub/college-basketballThe Ministry of Foreign Affairs has debunked claims of an ambassadorial nominees’ list circulating on social media, calling it fake and urging the public to disregard it. In a statement issued on Sunday, the ministry, through its acting spokesperson, Kimiebi Ebienfa, clarified that the appointment of ambassadors is the exclusive responsibility of the President. The statement emphasised that no such appointments have been made. “The Ministry of Foreign Affairs wishes to inform the general public to kindly disregard the fake list of Ambassadorial nominees, which is currently in circulation on some social media platforms. “The Ministry wishes to state unequivocally that the appointment of Ambassadors is the prerogative of Mr. President, and no such appointments have been made in that regard. The purported list should, therefore, be discountenanced,” the statement said. The ministry’s clarification follows growing concerns and confusion over the authenticity of the list of ambassadors.Ruud van Nistelrooy is reportedly set to be appointed as Leicester City's new manager, various British media outlets said on Wednesday. Van Nistelrooy recently left Manchester United after a short spell as interim manager and serving as assistant to Erik ten Hag. Leicester sacked Steve Cooper on Sunday after just 12 Premier League games in charge, with the Foxes 16th in the table and only one point above the relegation zone. Two of Van Nistelrooy's three wins in four games as United's caretaker boss in the past month came against Leicester in the League Cup and Premier League. The 48-year-old Dutchman has previous managerial experience from one year in charge of PSV Eindhoven from 2022 to 2023. Sky Sports reported that he could even be appointed in time to lead Leicester in their next game away at Brentford on Saturday. A prolific goalscorer, Van Nistelrooy enjoyed a glorious playing career, most notably at PSV, Man United and Real Madrid. (AFP)
Moody’s upgrades Sri Lanka’s rating to Caa1; outlook stable
AI is a Major Disruptor to Your Salesforce: How the Evolution of AI is Transforming Sales Teams
Neuroblastoma Drugs Market 2024-2031 Global Industry Analysis, Size, Share, Growth, Trends, and Forecast | Leading Players - United Therapeutics Corporation, APEIRON Biologics AG, Teva Pharmaceutical Industries Ltd 11-21-2024 08:58 PM CET | Health & Medicine Press release from: DataM Intelligence 4 Market Research LLP DataM Intelligence The latest report on Neuroblastoma Drugs Market offers valuable insights into emerging trends and pivotal developments within the market. It highlights significant growth opportunities that market participants can leverage, alongside strategic recommendations for capitalizing on these trends. This report serves as an indispensable tool for stakeholders seeking to deepen their understanding of the market landscape and identify actionable pathways for growth. By utilizing this in-depth analysis, stakeholders will gain the insights necessary to effectively adapt to shifting market conditions and strengthen their competitive position. Download a Free sample PDF (Use Corporate email ID to Get Higher Priority) at: - https://datamintelligence.com/download-sample/neuroblastoma-drugs-market The Global Neuroblastoma Drugs Market is expected to grow at a high CAGR during the forecast period (2024-2031). Market Dynamics The rising demand for anti-GD2 antibodies is expected to significantly drive the growth of the global neuroblastoma drugs market during the forecast period. Anti-GD2 monoclonal antibodies have emerged as a key therapeutic innovation in treating neuroblastoma, a challenging pediatric cancer. GD2, a cell surface antigen, is highly expressed on neuroblastoma cells. Targeting these antigens with anti-GD2 antibodies enables precise action against cancer cells while sparing healthy tissues, reducing the risk of systemic cytotoxic effects. This specificity has improved the treatment outcomes and overall quality of life for patients. For instance, Dinutuximab, the first FDA-approved anti-GD2 monoclonal antibody, has shown efficacy in treating high-risk neuroblastoma, becoming a cornerstone therapy in this segment. Its ability to trigger immune responses, such as antibody-dependent cell-mediated cytotoxicity (ADCC), has been crucial in combating neuroblastoma. The growing recognition of anti-GD2 therapies' effectiveness, coupled with their favorable safety profiles, has led to increasing prescriptions by healthcare professionals. Additionally, ongoing research and development of next-generation GD2-targeted therapies and combination regimens are anticipated to further expand the market. As awareness of neuroblastoma treatments grows and advancements in antibody-based cancer therapies continue, the demand for anti-GD2 antibodies will drive significant growth in the neuroblastoma drugs market. Key Developments: January 27, 2021, Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Waldenstrom's Macroglobulinemia. On-going Phase 1 study on CLR 131 in children, adolescents, and young adults with relapsed or refractory malignant solid tumors and recurrent or refractory malignant brain tumors, neuroblastoma for which there are no standard treatment options with curative potential. List of the Key Players in the Neuroblastoma Drugs Market: Cellectar Biosciences, INC, United Therapeutics Corporation, APEIRON Biologics AG, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services, Inc, MacroGenics, Bristol-Myers Squibb Company, Eli Lilly and Company, Marsala Biotech Inc, Pfizer Inc. Research Process: Both primary and secondary data sources have been used in the global Neuroblastoma Drugs Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges. Segment Covered in the Neuroblastoma Drugs Market: By Drug Type (Dinutuximab, Cisplatin, Doxorubicin, Vincristine, Etoposide, Others) By Distribution Channel (Hospital Pharmacies, Clinics, Cancer research institutes, Others) Regional Outlook: The global Neuroblastoma Drugs Market report focuses on six major regions: North America, South America, Europe, Asia Pacific, the Middle East, and Africa. Get Customization in the report as per your requirements+Exclusive Bundle & Multi-User Discounts: https://datamintelligence.com/customize/neuroblastoma-drugs-market Regional Analysis: The global Neuroblastoma Drugs Market report focuses on six major regions: North America, South America, Europe, Asia Pacific, the Middle East, and Africa. The report offers detailed insight into new product launches, new technology evolutions, innovative services, and ongoing R&D. The report discusses a qualitative and quantitative market analysis, including PEST analysis, SWOT analysis, and Porter's five force analysis. The Neuroblastoma Drugs Market report also provides fundamental details such as raw material sources, distribution networks, methodologies, production capacities, industry supply chain, and product specifications. **The full version of the report includes an in-depth analysis of emerging players and startups, which will provide valuable insights into the evolving market landscape and key strategies being adopted** Points Covered: ⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Neuroblastoma Drugs market segments, study objectives, and years considered. ⏩ Market Landscape: The competition in the Global Neuroblastoma Drugs Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies. ⏩ Companies Profiles: The global Neuroblastoma Drugs market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production. ⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study. ⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Neuroblastoma Drugs Market. ⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type. ⏩ Research Findings: This section of the report showcases the findings and analysis of the report. ⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided. Unlock Year-End Savings! Get Up to 30% Off: https://www.datamintelligence.com/buy-now-page?report=neuroblastoma-drugs-market Frequently Asked Questions ● What is the expected growth rate of the global Neuroblastoma Drugs market for the forecast period? ● What are the key driving factors that are responsible to shape the fate of the Neuroblastoma Drugs market during the forecast period? ● What will be the overall size of the market during the analysis period? ● What are the prominent market trends which influence the development of the Neuroblastoma Drugs market across various regions? ● Who are the key market players and the market strategies that have helped them to secure the leading position in the global Neuroblastoma Drugs market? ● What are the challenges and threats that are likely to act as a barrier to the growth of the Neuroblastoma Drugs market? ● What are the major opportunities that the companies can get to attain success in the world? Contact Us - Company Name: DataM Intelligence Contact Person: Sai Kiran Email: Sai.k@datamintelligence.com Phone: +1 877 441 4866 Website: https://www.datamintelligence.com About Us - DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology. Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele. This release was published on openPR.
The Lakshman Kadirgamar Institute of International Relations and Strategic Studies (LKI), in collaboration with the International Committee of the Red Cross (ICRC) hosted a panel discussion titled, “Artificial Intelligence (AI), Autonomous Weapons Systems (AWS) and contemporary challenges” at the LKI Lighthouse Auditorium on 19 December 2024. It was attended by diplomats, representatives of international organisations, senior officials of relevant Ministries and agencies, military personnel, leading researchers and university students. Delivering the keynote address at the event, the Foreign Affairs Ministry Additional Secretary for East Asia, the Middle East, and Africa Yasoja Gunasekera underscored the urgent need for global action to regulate Artificial Intelligence and Autonomous Weapons Systems. She emphasised that while AI has become integral to numerous sectors, its growing presence on the battlefield raises profound concerns regarding its application in weapon systems. The Additional Secretary recalled that it was under the Chairmanship of Sri Lanka in 2015, that the high contracting parties to the convention on Certain Conventional Weapons (CCW) agreed to elevate the discussion of LAWS from an informal expert led discussion to a State-led dialogue, leading to the establishment of the first meeting of the Group of Governmental Experts (GGE) at the 2016 CCW Review Conference. She noted that in addition to actively engaging in the GGE, in October 2021 Sri Lanka together with a wide cross regional group of 70 states co-sponsored the first Joint Statement on LAWS at the UNGA and supported the adoption of “the Pact for the Future” by the UNGA in September 2024. Sri Lanka strongly supports the negotiation of a legally binding instrument to prohibit and regulate LAWS and supports the UN Secretary General and the President of the ICRC’s joint appeal to establish new rules on AWS by 2026. Earlier welcoming the gathering, LKI Executive Director Ambassador Ravinatha Aryasinha said the event was intended to salute the role played by the ICRC which commemorated the 75th anniversary of the operation of the Geneva Conventions, without which the world might have been a different place. He recalled the ICRC’s contributions to Sri Lanka since establishing a presence in 1989, particularly during the armed conflict – escorting food and civilian convoys to the North and the East, facilitating immunisation drives, passing messages between the parties in conflict and enabling the return of the wounded and the dead on both sides, and post conflict assistance in mine clearance, disaster response, and in the search for missing persons. Across time, the ICRC had also played an important role in training the security forces on IHL compliance and engaged in prison visitations and supported the improvement of prison conditions. He observed that the theme of the discussion chosen on disarmament, besides being one where the ICRC and Sri Lanka closely collaborated globally, is the focus of several ongoing research endeavours of the LKI in recent times, along with ICT and its contemporary challenges. Delivering the opening remarks, ICRC Sri Lanka Head of Delegation Severine Chappaz focused on the continued relevance of IHL. Stressing that the main responsibility to apply IHL in good faith lies with States to mitigate human suffering, she underlined the importance of making IHL a national and international political priority. She also emphasised on aspects of IHL that are particularly relevant to Sri Lanka, including the post-conflict application of IHL, which applies specifically to the issue of missing persons, their right to be searched for, the right of their families to know the fate and whereabouts of their missing loved ones and the obligation to prevent people from going missing. She also referred to the significance of national integration of IHL where the National IHL committee of Sri Lanka plays a key role, training the armed forces in IHL, and the dissemination of IHL through academic and religious circles. In her remarks, Sri Lanka’s international engagement in the promotion and development of IHL, notably in the field of disarmament regulations, was also recognised. ICRC Regional Legal Advisor Prof. Andrei Kozik highlighted the novel humanitarian and legal challenges posed by technological developments including AI and AWS. Delving into the subject, he drew attention to the unique characteristics of AWS that heighten risks for civilians and raise challenges for IHL compliance. In his presentation, Prof. Kozik also clarified the ICRC’s position on AWS, stating that the ICRC calls for new rules that prohibit the use of “unpredictable” and “anti-personnel” autonomous weapons systems. It was noted that in this context, “unpredictability” refers to the discriminatory nature of AWS weapons while “anti-personnel” refers to autonomous weapons designed or used to target humans directly. The ICRC’s report titled “International Humanitarian Law and the challenges of contemporary armed conflicts” was referenced as a source to obtain an overview of some of the challenges for IHL posed by contemporary armed conflicts. The report broadly underscores the humanitarian consequences that could result from the potential loss of human control over the use of force in armed conflict. Sri Lankan Coordinator for the Global Campaign “Stop Killer Robots” Yanithra Kumaraguru underscored the critical role of ethics in shaping both the legal frameworks and the development of autonomous weapons, especially in areas where current laws may not provide clear guidance. She highlighted several key ethical concerns, including the challenge of ensuring that autonomous weapons comply with international humanitarian law principles and also questioned whether machines could reliably make life-and-death decisions without human biases, stressing the risks of errors that could lead to violations of human dignity. She further discussed the “moral accountability gap”, an ethical concern that extends beyond legal frameworks and asked whether responsibility for actions taken by autonomous weapons lies with designers, operators, or no one at all emphasising the dehumanising consequences of delegating such critical decisions to machines. Stressing the fact that some advocates for autonomous weapons argue that these technologies could lead to greater precision and fewer civilian casualties, Kumaraguru countered that those technological limitations, the unpredictable nature of conflict and the human realities of conflict make such claims overly idealistic. Defence Ministry Director of Media and Spokesman, and Institute of National Security Studies (INSS) Head Colonel Nalin Herath while acknowledging the ethical challenges posed highlighted the transformative impact of AI on modern warfare emphasising its potential for operational efficiency, noted how such weapons are reshaping combat strategies and in distinguishing civilians from military targets. He raised concern about the growing access of non-state actors to advanced technologies, which heightens unpredictability in conflicts and cautioned against the dangers posed by AI in terms of misinformation and disinformation. Stressing the absence of a global consensus on regulating AI in warfare, he called for caution and cooperation to ensure ethical use of AI and to prevent its misuse. National Innovation Agency (NIA) Chief Innovation Officer and Pugwash Sri Lanka Past President Prof. Ajith De Alwis addressed the dual-use nature of science, technology, and innovation, particularly in the context of autonomous weapons systems and AI. He noted that since the wright brothers’ revolutionary invention of flight in 1903 which within a decade was quickly adapted for bombing, historically technology had been weaponised. He pointed to the futility of questioning whether blame can be apportioned to autonomous weapons used in wars, what is more crucial is that states create the conditions to prevent wars from taking place in the first place. He emphasised the need for better prioritising of the use of AWS, rather than banning per se, and advocated for leveraging AI and autonomous systems for humanity’s benefit rather than their weaponisation. Pointing to the climate issue where time was running out and the emission trajectories being put into wrong trajectories by all the conflicts going on, he asked that researchers must be persuaded to become more socially responsible, as the scientists who walked out of the “Manhattan Project” which pursued the creation of the atomic bomb. He also advocated strengthening a UN led global mechanism supporting whistle blowing and asked that we push ourselves to value humanity more - touching on the Pugwash principles. Ambassador Aryasinha who moderated the panel discussion, reflecting on the challenges faced as Sri Lanka’s Permanent Representative in Geneva in presiding over the CCW during Sri Lanka’ Presidency of the CCW in 2015/2016 which secured a consensus to commence the discussion of LAWS at the level of States parties nearly a decade ago, regretted that movement had been slow and that many relevant States needed for effective regulation of AWS, opposed or remained ambivalent in supporting such regulation. While the ethical and legal arguments were not in doubt, greater moral persuasion and compromise would be needed to also carry those who already possess or are on the verge of possessing AWS from using them, as war fronts expand and armies seek to minimise casualties. During an almost hour-long discussion that followed, the audience pointed to the absence of a universal definition, highlighted gaps in International Humanitarian Law (IHL), the politicisation of AWS, the advances and limitations in distinguishing combatants from non-combatants, opaque decision-making, the ethical and legal issues concerned and the slow pace of regulation. They also impressed on the need for a Sri Lanka national policy on AI and AWS, suggested that smaller nations like Sri Lanka press for reforms to protect weaker states. Members of the panel explored the tension between technological innovation and ethical responsibility, emphasising alignment with IHL principles like distinction and proportionality. They underscored transparency in AI’s “black box” decision-making, gaps in IHL related to espionage and information warfare, and the relevance of Article 36 of the Geneva Conventions in reviewing new weapons. The session concluded by stressing collaboration, culturally informed ethical considerations, and practical, legally binding measures to balance technological advances with human oversight.
- 11 super game apk
- 7xm xyz
- online game download
- niceph slot
- apollo game slot online
- mnl168 free download ios
- fortune for ox in 2024
- 777bet casino
- *,TAD.ZT$iHTE]%O[5&piȜĤ%ړH"x Ζ't0D@DxMexhIַ{;u?.x5J߶:$Ld0_nSMDA!KA OaYFyi '䗄Rer%g%G E4r6
FB1jDSHI fr?ҮC$6>7sX "љ䷺ - uR֏7"T» g "s\3kIHq. |wKm +hԥ>MDq5 , 乃'aKu] '/,qqChfcNDRNސ Vz/5Ҫ3@j* }d/P*MG Gd k$@U W/j:ADã !%9|Lzi_^ ,8qh/Bz;L^} ~ \kqI u __(ze&a]b!>BxOS``///+D"еokl6@tE B mU&U x@#Ȱ@0OC3Xꊺ2Vui U!:uЅ#R s8`(Ck)99\7ŞRu'c(6F21?K MMDbu% .xK}J*5|4^.;\KJBf9)!$Pt>'qqj6Qs Ox^"y Yetf7*UPqV a[e% ^! O {
-
"> -
"> -
"> -
">
